Prognostic Factors and Skeletal-Related Events in Patients with Small Cell Lung Cancer with Bone Metastases at the Time of Diagnosis

Oncology ◽  
2016 ◽  
Vol 90 (2) ◽  
pp. 103-111 ◽  
Author(s):  
Eun Joo Kang ◽  
Suk Young Lee ◽  
Hong Jun Kim ◽  
Kyung Hoon Min ◽  
Gyu Young Hur ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Bone Metastases ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Skeletal Related Events

scholarly journals Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort

2016 ◽  
Vol 7 (14) ◽  
pp. 2110-2116 ◽  
Author(s):  
Katrin Conen ◽  
Raphael Hagmann ◽  
Viviane Hess ◽  
Alfred Zippelius ◽  
Sacha I. Rothschild
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Bone Metastases ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Patient Cohort ◽  
Skeletal Related Events

scholarly journals Prognostic factors in patients with skeletal-related events at non-small-cell lung cancer diagnosis

2017 ◽  
Vol 7 (5) ◽  
pp. 897-902 ◽  
Author(s):  
Hiroyuki Tominaga ◽  
Takao Setoguchi ◽  
Hirofumi Shimada ◽  
Satoshi Nagano ◽  
Hiromi Sasaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Cancer Diagnosis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Diagnosis ◽  
Skeletal Related Events

Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases

Lung Cancer ◽  
2011 ◽  
Vol 71 (1) ◽  
pp. 89-93 ◽  
Author(s):  
Jong-Mu Sun ◽  
Jin Seok Ahn ◽  
Soohyeon Lee ◽  
Jung A. Kim ◽  
Jeeyun Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Skeletal Related Events

scholarly journals Skeletal related events in non-small cell lung cancer with bone metastases

2010 ◽  
Vol 5 (2) ◽  
pp. 145-151
Author(s):  
Koji Sato ◽  
Nobuhiro Saruki ◽  
Hisashi Hosaka ◽  
Tadashi Murakami ◽  
Yuki Takada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Bone Metastases ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Skeletal Related Events

scholarly journals Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

2021 ◽  
Vol 19 (8) ◽  
pp. 915-921
Author(s):  
Angel Qin ◽  
Songzhu Zhao ◽  
Abdul Miah ◽  
Lai Wei ◽  
Sandipkumar Patel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Bone Metastases ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Skeletal Related Events

Background: Bone metastases and skeletal-related events (SREs) are a frequent cause of morbidity in patients with metastatic non–small cell lung cancer (mNSCLC). Data are limited on bone metastases and SREs in patients with mNSCLC treated using immune checkpoint inhibitors (ICIs), and on the efficacy of bone-modifying agents (BMAs) in this setting. Here we report the incidence, impact on survival, risk factors for bone metastases and SREs, and impact of BMAs in patients with mNSCLC treated with ICIs in a multi-institutional cohort. Patients and Methods: We conducted a retrospective study of patients with mNSCLC treated with ICIs at 2 tertiary care centers from 2014 through 2017. Overall survival (OS) was compared between patients with and without baseline bone metastases using a log-rank test. A Cox regression model was used to evaluate the association between OS and the presence of bone metastases at ICI initiation, controlling for other confounding factors. Results: We identified a cohort of 330 patients who had received ICIs for metastatic disease. Median patient age was 63 years, most patients were treated in the second line or beyond (n=259; 78%), and nivolumab was the most common ICI (n=211; 64%). Median OS was 10 months (95% CI, 8.4–12.0). In our cohort, 124 patients (38%) had baseline bone metastases, and 43 (13%) developed SREs during or after ICI treatment. Patients with bone metastases had a higher hazard of death after controlling for performance status, histology, line of therapy, and disease burden (hazard ratio, 1.57; 95% CI, 1.19–2.08; P=.001). Use of BMAs was not associated with OS or a decreased risk of SREs. Conclusions: Presence of bone metastases at baseline was associated with a worse prognosis for patients with mNSCLC treated with ICI after controlling for multiple clinical characteristics. Use of BMAs was not associated with reduced SREs or a difference in survival.

Sign in / Sign up

Export Citation Format

Share Document